US6828415B2
(en)
*
|
1993-02-19 |
2004-12-07 |
Zentaris Gmbh |
Oligopeptide lyophilisate, their preparation and use
|
DE69923795T2
(de)
*
|
1998-12-15 |
2006-03-16 |
Takeda Pharmaceutical Co. Ltd. |
Verfahren zur Herstellung biologisch-abbaubarer Polyester
|
NZ516466A
(en)
|
1999-07-15 |
2003-02-28 |
Takeda Chemical Industries Ltd |
Sustained release compositions, process for producing the same and use thereof
|
EP1297850B1
(fr)
|
2000-07-05 |
2015-08-19 |
Takeda Pharmaceutical Company Limited |
Preparations medicinales pour le traitement des maladies dependant des hormones sexuelles
|
ATE322513T1
(de)
|
2000-08-07 |
2006-04-15 |
Wako Pure Chem Ind Ltd |
Milchsäurepolymer und verfahren zu dessen herstellung
|
DE10040700A1
(de)
|
2000-08-17 |
2002-02-28 |
Asta Medica Ag |
Salze von biologisch aktiven Peptiden, ihre Herstellung und Verwendung
|
AU2002218494A1
(en)
*
|
2000-11-29 |
2002-06-11 |
Takeda Chemical Industries Ltd. |
Medicinal compositions and process for producing the same
|
WO2002047722A1
(fr)
*
|
2000-12-15 |
2002-06-20 |
Takeda Chemical Industries, Ltd. |
Compositions medicinales agoniste ou antagoniste de la gonadoliberine non peptidyl, methode de production et utilisation desdites compositions
|
EP1374855A1
(fr)
*
|
2001-03-30 |
2004-01-02 |
Takeda Chemical Industries, Ltd. |
Solutions medicinales
|
CA2444727A1
(fr)
*
|
2001-04-25 |
2002-11-07 |
Takeda Chemical Industries, Ltd. |
Remedes contre la recurrence postoperative du cancer du sein chez les femmes en premenopause
|
TW200526267A
(en)
|
2001-06-29 |
2005-08-16 |
Takeda Chemical Industries Ltd |
Controlled release composition and method of producing the same
|
TWI225416B
(en)
*
|
2001-06-29 |
2004-12-21 |
Takeda Chemical Industries Ltd |
Sustained-release composition and process for producing the same
|
DE60239207D1
(de)
*
|
2001-08-10 |
2011-03-31 |
Takeda Pharmaceutical |
Gnrh-agonistische kombinationsmittel
|
MXPA04003433A
(es)
|
2001-10-10 |
2004-08-11 |
Pf Medicament |
Microesferas biodegradables de liberacion prolongada y metodo para preparar las mismas.
|
EP1444988A4
(fr)
|
2001-11-13 |
2007-04-25 |
Takeda Pharmaceutical |
Agents anticancer
|
AU2002367105A1
(en)
*
|
2001-12-26 |
2003-07-15 |
Takeda Chemical Industries, Ltd. |
Novel microsphere and method for production thereof
|
US7175642B2
(en)
|
2002-04-19 |
2007-02-13 |
Pelikan Technologies, Inc. |
Methods and apparatus for lancet actuation
|
US7674232B2
(en)
|
2002-04-19 |
2010-03-09 |
Pelikan Technologies, Inc. |
Method and apparatus for penetrating tissue
|
DK1532985T3
(en)
*
|
2002-06-25 |
2016-12-05 |
Takeda Pharmaceuticals Co |
PROCEDURE FOR PREPARING A COMPOSITION WITH LONG-TERM RELEASE
|
AU2003266581A1
(en)
*
|
2002-09-24 |
2004-04-19 |
Asahi Kasei Chemicals Corporation |
Glycolic acid copolymer and method for production thereof
|
US20070207211A1
(en)
*
|
2003-04-10 |
2007-09-06 |
Pr Pharmaceuticals, Inc. |
Emulsion-based microparticles and methods for the production thereof
|
PT1615959E
(pt)
*
|
2003-04-10 |
2013-08-29 |
Evonik Corp |
Um método para a produção de micropartículas à base de emulsão
|
US8871269B2
(en)
*
|
2003-07-15 |
2014-10-28 |
Evonik Corporation |
Method for the preparation of controlled release formulations
|
CA2533592C
(fr)
*
|
2003-07-23 |
2015-11-10 |
Pr Pharmaceuticals, Inc. |
Compositions a liberation controlee
|
US20070276024A1
(en)
*
|
2003-10-09 |
2007-11-29 |
Inverseon , Inc. |
Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists
|
AU2004279438A1
(en)
*
|
2003-10-09 |
2005-04-21 |
Inverseon, Inc. |
Methods for treating diseases and conditions with inverse agonists
|
TW200529890A
(en)
*
|
2004-02-10 |
2005-09-16 |
Takeda Pharmaceutical |
Sustained-release preparations
|
TW200613012A
(en)
*
|
2004-07-02 |
2006-05-01 |
Takeda Pharmaceuticals Co |
Sustained-release composition, process for producing the same and use of the same
|
US7528175B2
(en)
*
|
2004-10-08 |
2009-05-05 |
Inverseon, Inc. |
Method of treating airway diseases with beta-adrenergic inverse agonists
|
US20060222716A1
(en)
*
|
2005-04-01 |
2006-10-05 |
Joseph Schwarz |
Colloidal solid lipid vehicle for pharmaceutical use
|
WO2006137953A1
(fr)
|
2005-04-01 |
2006-12-28 |
The Regents Of The Univerisity Of California |
Nucleosides phosphono-pent-2-en-1-yle et analogues
|
US20090156545A1
(en)
*
|
2005-04-01 |
2009-06-18 |
Hostetler Karl Y |
Substituted Phosphate Esters of Nucleoside Phosphonates
|
DE602006000381T2
(de)
*
|
2005-04-28 |
2008-12-18 |
Nipro Corp., Osaka |
Bioabsorbierbare pharmazeutische Zusammensetzung enthaltend einen PLGA-Copolymer
|
US20070027107A1
(en)
*
|
2005-07-29 |
2007-02-01 |
Curt Hendrix |
Compositions and methods for treating estrogen-dependent diseases and conditions
|
RU2457854C2
(ru)
|
2005-12-30 |
2012-08-10 |
Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи Лимитед |
Длительное высвобождение нейрегулина для улучшения сердечной функции
|
CN101443314B
(zh)
*
|
2006-03-13 |
2014-04-09 |
杏林制药株式会社 |
作为gsk-3抑制剂的氨基喹诺酮类
|
RU2008136317A
(ru)
*
|
2006-03-13 |
2010-04-20 |
Инсайсив Фармасьютикалз, Инк. (US) |
Способы и композиции для лечения диагностикой сердечной недостаточности
|
AU2007225207A1
(en)
*
|
2006-03-13 |
2007-09-20 |
Encysive Pharmaceuticals, Inc. |
Formulations of sitaxsentan sodium
|
US20080026061A1
(en)
*
|
2006-06-22 |
2008-01-31 |
Reichwein John F |
Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
|
WO2008036379A2
(fr)
|
2006-09-21 |
2008-03-27 |
Activx Biosciences, Inc. |
Inhibiteurs de serine hydrolase
|
WO2008057604A2
(fr)
*
|
2006-11-08 |
2008-05-15 |
The Regents Of The University Of California |
Agents thérapeutiques contenant de petites molécules, synthèses d'analogues et de dérivés et leurs procédés d'utilisation
|
WO2008075762A1
(fr)
*
|
2006-12-18 |
2008-06-26 |
Takeda Pharmaceutical Company Limited |
Composition à libération prolongée et procédé de production correspondant
|
US7892776B2
(en)
|
2007-05-04 |
2011-02-22 |
The Regents Of The University Of California |
Screening assay to identify modulators of protein kinase A
|
RU2343908C1
(ru)
*
|
2007-09-05 |
2009-01-20 |
Руслан Дмитриевич Илюк |
Средство для профилактики и лечения алкоголизма и способ его применения
|
JP5426552B2
(ja)
*
|
2007-09-11 |
2014-02-26 |
杏林製薬株式会社 |
Gsk−3阻害剤としてのシアノアミノキノロン及びテトラゾロアミノキノロン
|
MX2010002662A
(es)
|
2007-09-12 |
2010-04-09 |
Activx Biosciences Inc |
Aminoquinolonas espirociclicas como inhibidores de gsk-3.
|
WO2009139880A1
(fr)
*
|
2008-05-13 |
2009-11-19 |
Celgene Corporation |
Composés et compositions de thioxo-isoindoline, et procédés d'utilisation
|
AR075633A1
(es)
|
2009-02-27 |
2011-04-20 |
Ambit Biosciences Corp |
Compuestos moduladores de jak quinasa y sus metodos de uso
|
WO2010104205A1
(fr)
|
2009-03-11 |
2010-09-16 |
Kyorin Pharmaceutical Co., Ltd. |
7-cycloalkylaminoquinolones comme inhibiteurs de la gsk-3
|
CA2770454A1
(fr)
|
2009-08-19 |
2011-02-24 |
Ambit Biosciences Corporation |
Composes biaryles et procedes d'utilisation de ceux-ci
|
WO2011069002A1
(fr)
|
2009-12-02 |
2011-06-09 |
Alquest Therapeutics, Inc. |
Composés d'organosélénium et leurs utilisations
|
WO2011079313A1
(fr)
*
|
2009-12-23 |
2011-06-30 |
Map Pharmaceuticals, Inc. |
Analogues d'ergoline
|
WO2011150198A1
(fr)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Composés azolyle urée et leurs procédés d'utilisation
|
WO2011150201A2
(fr)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Composés azolylamide et leurs procédés d'utilisation
|
EP2611789A1
(fr)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
Composés de quinazoline et leurs méthodes d'utilisation
|
MX2013006166A
(es)
*
|
2010-12-15 |
2013-08-01 |
3M Innovative Properties Co |
Fibras degradables.
|
CN103732611B
(zh)
|
2011-01-10 |
2016-06-01 |
伊沃恩有限公司 |
β-肾上腺素能反向激动剂用于戒烟的用途
|
AR082266A1
(es)
*
|
2011-05-13 |
2012-11-28 |
Univ Nac Del Litoral |
Microparticula inyectable de liberacion controlada
|
KR20140042868A
(ko)
|
2011-06-23 |
2014-04-07 |
맵 파마슈티컬스, 인코포레이티드 |
신규한 플루오로에르골린 유사체
|
WO2013056070A2
(fr)
|
2011-10-14 |
2013-04-18 |
Ambit Biosciences Corporation |
Composés hétérocycliques et procédés d'utilisation associés
|
EP2793580A4
(fr)
|
2011-12-19 |
2015-05-20 |
Map Pharmaceuticals Inc |
Nouveaux dérivés d'iso-ergoline
|
US8946420B2
(en)
|
2011-12-21 |
2015-02-03 |
Map Pharmaceuticals, Inc. |
Neuromodulatory compounds
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
SG11201504931SA
(en)
|
2012-12-21 |
2015-07-30 |
Map Pharmaceuticals Inc |
Novel methysergide derivatives
|
CA2922230A1
(fr)
|
2013-08-30 |
2015-03-05 |
Ambit Biosciences Corporation |
Composes de biaryle acetamide et procedes d'utilisation de ceux-ci
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
AR101476A1
(es)
|
2014-08-07 |
2016-12-21 |
Acerta Pharma Bv |
Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
|
EP3191100A4
(fr)
|
2014-09-12 |
2018-05-30 |
Tobira Therapeutics, Inc. |
Polythérapie au cenicriviroc pour le traitement de la fibrose
|
WO2016065264A1
(fr)
|
2014-10-24 |
2016-04-28 |
Biogen Ma Inc. |
Dérivés de diterpénoïdes et leurs procédés d'utilisation
|
BR112017015510A2
(pt)
|
2015-01-20 |
2018-01-30 |
Xoc Pharmaceuticals Inc |
composto de fórmula estrutural (i), método de tratamento e/ou prevenção, método de agonização do receptor d2 em um indivíduo, método de antagonização do receptor d3 em um indivíduo, método de agonização do receptor 5-ht1d em um indivíduo, método de agonização do receptor 5-ht1a em um indivíduo, método de agonização seletiva do receptor 5-ht1d em vez do receptor 5-ht1b em um indivíduo, método de agonização seletiva do re-ceptor 5-ht2c em vez do receptor 5-ht2a ou 5-ht2b em um indivíduo, método de agonização do receptor 5-ht2c em um indivíduo, método de fornecimento de atividade antagonista funcional no receptor 5-ht2b ou receptor 5-ht7, e, método de fornecimento de atividade antagonista funcional nos receptores adrenérgicos em um indivíduo
|
US9657020B2
(en)
|
2015-01-20 |
2017-05-23 |
Xoc Pharmaceuticals, Inc. |
Ergoline compounds and uses thereof
|
CA2985123C
(fr)
|
2015-08-17 |
2021-04-13 |
Antonio Gualberto |
Methodes de traitement de patients atteints du cancer avec des inhibiteurs de farnesyltransferase
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
CN108712904B
(zh)
|
2016-01-08 |
2022-08-02 |
细胞基因公司 |
2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的固体形式以及其药物组合物和用途
|
ES2832475T3
(es)
|
2016-01-08 |
2021-06-10 |
Celgene Corp |
Compuestos antiproliferativos y sus composiciones farmacéuticas y usos
|
WO2017180794A1
(fr)
|
2016-04-13 |
2017-10-19 |
Skyline Antiinfectives, Inc. |
Acides hydroxamiques de bêta-lactame o-sulfatés deutérés et bêta-lactames n-sulfatés deutérés
|
WO2017184968A1
(fr)
|
2016-04-22 |
2017-10-26 |
Kura Oncology, Inc. |
Méthodes de sélection de patients atteints de cancer pour le traitement avec des inhibiteurs de farnésyltransférase
|
MY190861A
(en)
|
2016-11-03 |
2022-05-12 |
Kura Oncology Inc |
Farnesyltransferase inhibitors for use in methods of treating cancer
|
WO2018089692A1
(fr)
|
2016-11-09 |
2018-05-17 |
Phloronol, Inc. |
Dérivés d'eckol, procédés de synthèse et utilisations associées
|
US9956215B1
(en)
|
2017-02-21 |
2018-05-01 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
MX2019009821A
(es)
|
2017-02-21 |
2019-12-02 |
Kura Oncology Inc |
Metodos para tratar cancer con inhibidores de farnesiltransferasa.
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
CA3064274A1
(fr)
|
2017-06-01 |
2018-12-06 |
Xoc Pharmaceuticals, Inc. |
Derives d'ergoline destines a etre utilises en medecine
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
BR112020002591A2
(pt)
|
2017-08-07 |
2020-07-28 |
Kura Oncology, Inc. |
método para o tratamento de câncer
|
WO2019113269A1
(fr)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Méthodes de traitement de patients cancéreux avec des inhibiteurs de la farnésyltransférase
|
CN113286591A
(zh)
|
2018-11-01 |
2021-08-20 |
库拉肿瘤学公司 |
用法尼基转移酶抑制剂治疗癌症的方法
|
US20230078755A1
(en)
|
2018-12-19 |
2023-03-16 |
Shy Therapeutics, Llc |
Compounds that Interact with the RAS Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease
|
JP2022514654A
(ja)
|
2018-12-21 |
2022-02-14 |
クラ オンコロジー, インコーポレイテッド |
扁平上皮癌のための治療法
|
US11447468B2
(en)
|
2019-02-06 |
2022-09-20 |
Dice Alpha, Inc. |
IL-17 ligands and uses thereof
|
US20220142983A1
(en)
|
2019-03-01 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
WO2020190604A1
(fr)
|
2019-03-15 |
2020-09-24 |
Kura Oncology, Inc. |
Méthodes de traitement de patients cancéreux avec des inhibiteurs de la farnésyltransférase
|
TW202043487A
(zh)
|
2019-03-29 |
2020-12-01 |
美商庫拉腫瘤技術股份有限公司 |
以法尼基轉移酶(farnesyltransferase)抑制劑治療鱗狀細胞癌之方法
|
US20220168296A1
(en)
|
2019-04-01 |
2022-06-02 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
WO2020223583A1
(fr)
|
2019-05-02 |
2020-11-05 |
Kura Oncology, Inc. |
Méthodes de traitement de la leucémie myéloïde aiguë avec des inhibiteurs de la farnésyltransférase
|
EP4031534A1
(fr)
|
2019-09-16 |
2022-07-27 |
Dice Alpha, Inc. |
Modulateurs d'il-17a et leurs utilisations
|
CA3179635A1
(fr)
|
2020-05-29 |
2021-12-02 |
Boulder Bioscience Llc |
Procedes pour une thrombectomie endovasculaire amelioree a l'aide de 3,3'-diindolylmethane
|
US20230227466A1
(en)
|
2020-06-18 |
2023-07-20 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
EP4149471A4
(fr)
|
2020-06-30 |
2024-07-10 |
Prosetta Biosciences Inc |
Dérivés d'isoquinoléine, leurs procédés de synthèse et leurs utilisations
|
US20240309015A1
(en)
|
2021-01-27 |
2024-09-19 |
Shy Therapeutics, Llc |
Methods for the Treatment of Fibrotic Disease
|
EP4284377A1
(fr)
|
2021-01-27 |
2023-12-06 |
Shy Therapeutics LLC |
Méthodes pour le traitement d'une maladie fibrotique
|
KR20230169979A
(ko)
|
2021-03-10 |
2023-12-18 |
다이스 몰레큘스 에스브이, 인크. |
알파 v 베타 6 및 알파 v 베타 1 인테그린 억제제 및 그의 용도
|
WO2022226166A1
(fr)
|
2021-04-22 |
2022-10-27 |
Protego Biopharma, Inc. |
Imidazolidinediones et imidazolidinones spirocycliques pour le traitement d'une amylose à chaîne légère
|
EP4347568A1
(fr)
|
2021-05-27 |
2024-04-10 |
Protego Biopharma, Inc. |
Hétéroaryl-diamides activateurs d'ire1/xbp1s
|
EP4402124A1
(fr)
|
2021-10-22 |
2024-07-24 |
Prosetta Biosciences, Inc. |
Nouveaux agents thérapeutiques antiviraux pan-respiratoires à petites molécules ciblant l'hôte
|
KR102709458B1
(ko)
*
|
2021-11-23 |
2024-09-23 |
한국화학연구원 |
서방출 클로니딘 미립구형 주사제 및 그의 제조방법
|
AU2022399572A1
(en)
|
2021-11-30 |
2024-05-02 |
Kura Oncology, Inc. |
Macrocyclic compounds having farnesyltransferase inhibitory activity
|
US11981694B2
(en)
|
2022-01-03 |
2024-05-14 |
Lilac Therapeutics, Inc. |
Acyclic thiol prodrugs
|
WO2023129577A1
(fr)
|
2022-01-03 |
2023-07-06 |
Lilac Therapeutics, Inc. |
Promédicaments à base de thiol cyclique
|
WO2023160583A1
(fr)
*
|
2022-02-22 |
2023-08-31 |
上海云晟研新生物科技有限公司 |
Sel médicinal de cariprazine et forme cristalline de celui-ci, composition pharmaceutique, procédé de préparation et utilisation associés
|
US20230348909A1
(en)
|
2022-03-30 |
2023-11-02 |
Biomarin Pharmaceutical Inc. |
Dystrophin exon skipping oligonucleotides
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
AR129053A1
(es)
|
2022-04-14 |
2024-07-10 |
Bristol Myers Squibb Co |
Nuevos compuestos gspt1 y métodos de uso de los nuevos compuestos
|
WO2023201348A1
(fr)
|
2022-04-15 |
2023-10-19 |
Celgene Corporation |
Procédés de prédiction de la réactivité d'un lymphome à un médicament et méthodes de traitement du lymphome
|
TW202406557A
(zh)
|
2022-05-05 |
2024-02-16 |
美商拜奧馬林製藥公司 |
治療杜興氏肌肉失養症之方法
|
US20240158370A1
(en)
|
2022-09-09 |
2024-05-16 |
Innovo Therapeutics, Inc. |
CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS
|
US20240131005A1
(en)
|
2022-09-30 |
2024-04-25 |
Boulder Bioscience Llc |
Compositions and methods for treating non-hemorrhagic closed head injury
|
WO2024092037A1
(fr)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Composés de pyridone contenant un spirocycle
|
US20240174673A1
(en)
|
2022-10-26 |
2024-05-30 |
Protego Biopharma, Inc. |
Spirocycle Containing Pyridine Compounds
|
US20240174695A1
(en)
|
2022-10-26 |
2024-05-30 |
Protego Biopharma, Inc. |
Spirocycle Containing Bicyclic Heteroaryl Compounds
|
WO2024118810A1
(fr)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Activateurs de ire1/xbp1 diamide de pyrazole cyclique
|
WO2024118801A1
(fr)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Diamides hétéroaryles linéaires comme activateurs d'ire1/xbp1s
|